Primary CoQ10 deficiency
Primary coenzyme Q10 (CoQ10) deficiency is a group of rare inherited disorders in which the body cannot build CoQ10 at all. It is the one setting where CoQ10 is a genuine, disease-modifying treatment rather than a marginal supplement: started early and at high doses, it can halt or partly reverse the disease — though the response depends on the gene involved, and is weakest when the brain is affected.
If you or your child has a confirmed primary CoQ10 deficiency, high-dose CoQ10 is a specialist treatment worth starting early. It is not a reason for anyone else to take CoQ10; the low levels that come with ageing, statins or chronic illness are a different thing.
What it is
CoQ10 is a fat-soluble molecule that carries electrons in mitochondria, the cell's power plants, and works as an antioxidant in cell membranes. Normally the body makes its own. In primary CoQ10 deficiency, a person inherits two faulty copies of a gene in the CoQ10-building pathway — COQ2, COQ6, COQ8B, PDSS1/2 and others — so the body cannot build the molecule at all.[1]
This is categorically different from the "secondary" deficiency of ageing, statins or chronic illness that drives ordinary consumer use. There the body still makes CoQ10, only less of it, and the benefit of supplementing is at best marginal.
What treatment can do
Early, high-dose oral CoQ10 can halt or partly reverse the disease. The clearest responses are in a steroid-resistant kidney disease (nephrotic syndrome, in which the kidneys leak protein) and in some of the neurological forms.[2]
Where it falls short
- It depends on the gene and the organ. Response is best for the kidney-predominant forms and much weaker for the brain-predominant ones, where the blood–brain barrier limits how much CoQ10 reaches the central nervous system.
- Some patients do not respond at all.
- Timing matters. Treatment must start early to work.[3]
A related lead: multiple system atrophy
Multiple system atrophy is a rare disease of the nervous system, linked to faulty variants of one of the same CoQ10-building genes (COQ2). In a 2023 phase 2 trial of 139 patients, 1,500 mg a day of ubiquinol, the reduced form of CoQ10, for 48 weeks slightly slowed the worsening of a standard examination score of movement problems.[4] It needs confirmation, and it does not carry over to Parkinson's disease, Huntington's disease or dementia, where human trials have been disappointing (see Coenzyme Q10).
Why it matters beyond the rare cases
The condition is rare, so it does not change the calculus for most readers. It is the cleanest example of a pattern that runs through the CoQ10 evidence: supplementation works where a true deficit exists, and does little where it does not.
What to do
- Treatment belongs with a specialist in inherited metabolic or kidney disease, who will confirm the gene and set the dose.
- Start early. The response depends on treating before damage is established.
- Expect a partial response in brain-predominant forms, and judge it against the specialist's measures rather than hoping for a cure.